Phipps Chad F sold $295K of ZBH

Phipps Chad F (See remarks below.) sold 3,000 shares of ZIMMER BIOMET HOLDINGS, INC. (ZBH) at $98.35 ($0.30M total) on 2026-09-04.

Original reporting
SEC EDGAR · Phipps Chad F
Published Sep 9, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ZBH
Neutral
low confidence
Mentioned
$ZBH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZBHNeutralLow
01

Why it matters

Traders may note insider selling as a sentiment datapoint, but there is no accompanying company-specific catalyst (earnings, guidance, deal, or enforcement).

02

Market read

A modest officer open-market sale is unlikely to drive a durable repricing without other fundamental news.

03

What to watch

The filing does not indicate a 10b5-1 plan, but it also provides no context on motivation, option exercises, or compensation timing.

Relevance 4/10Novelty 2/10Timing: filed 2026-09-09 after-hours; transaction dated 2026-09-04

Background

The article is an SEC Form 4 insider transaction disclosure for Zimmer Biomet Holdings, Inc.

Company-level read

Ticker impact

$ZBHNeutralLow confidence
Context

SEC Form 4 shows officer Phipps Chad F sold 3,000 ZBH shares at $98.3500 on 2026-09-04 for about $295,050.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The transaction is modest in dollar terms and is an open-market sale by an officer, not a buy, guidance change, or regulatory/legal event.

Market effects

No clear sector read-through from a single, modest insider sale.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, so the signal may be overstated.

Key entities

  • Zimmer Biomet Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Phipps Chad F

    Officer who sold 3,000 shares of ZBH on 2026-09-04.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.